Minematsu Tsuyoshi, Hashimoto Tadashi, Aoki Toshiko, Usui Takashi, Kamimura Hidetaka
Drug Metabolism Research Laboratories, Astellas Pharma Inc., 1-8 Azusawa 1-chome, Itabashiku, Tokyo 174-8511, Japan.
Drug Metab Dispos. 2008 Aug;36(8):1496-504. doi: 10.1124/dmd.107.019828. Epub 2008 Apr 28.
Zonampanel monohydrate ([2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl] acetic acid monohydrate, YM872) is a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist. In humans, almost all administered zonampanel is excreted in the urine unchanged. Furthermore, zonampanel is transported by human organic anion transporter (OAT) 1, and OAT3 but not by OAT2, suggesting the contribution of OATs to renal excretion. In rats also, zonampanel is predominantly eliminated via urine but partly also via bile as the unchanged form. In this study, the molecular mechanism of the excretion of zonampanel was elucidated using cells expressing rat Oat1, Oat2, and Oat3. Furthermore, zonampanel (15 mg/kg) was given i.v. to rats with or without probenecid (50 mg/kg) or cimetidine (40 mg/kg), and pharmacokinetic parameters were compared. Zonampanel inhibited the uptake of typical substrates by Oat1, Oat2, and Oat3 with inhibition constant (K(i)) values of 7.02 to 10.4 microM. A time- and saturable concentration-dependent increase in [14C]zonampanel uptake was observed in these cells [Michaelis-Menten constant (K(m)) values: 13.4 to 53.6 microM]. Probenecid and cimetidine inhibited [14C]zonampanel uptake by Oats. In in vivo experiments, probenecid and cimetidine decreased intrinsic clearance for both the renal secretion and biliary excretion of zonampanel. Considering the tissue distribution and localization of each transporter, these results suggest that in rats zonampanel is taken up from the blood into proximal tubular cells via Oat1 and Oat3 and, unlike the case in humans, also into hepatocytes via Oat2 and Oat3. The interspecies differences in the excretion of zonampanel between rats and humans may thus be explained by those in the substrate selectivity and tissue distribution of OATs.
一水合佐南帕奈([2,3 - 二氧代 - 7 -(1H - 咪唑 - 1 - 基)- 6 - 硝基 - 1,2,3,4 - 四氢 - 1 - 喹喔啉基]乙酸一水合物,YM872)是一种新型的α - 氨基 - 3 - 羟基 - 5 - 甲基异恶唑 - 4 - 丙酸受体拮抗剂。在人体内,几乎所有给药的佐南帕奈都以原形经尿液排出。此外,佐南帕奈可由人类有机阴离子转运体(OAT)1和OAT3转运,但不能由OAT2转运,这表明OATs对肾脏排泄有作用。在大鼠中,佐南帕奈也主要通过尿液排泄,但部分也以原形经胆汁排泄。在本研究中,利用表达大鼠Oat1、Oat2和Oat3的细胞阐明了佐南帕奈排泄的分子机制。此外,给有或无丙磺舒(50 mg/kg)或西咪替丁(40 mg/kg)的大鼠静脉注射佐南帕奈(15 mg/kg),并比较药代动力学参数。佐南帕奈抑制Oat1、Oat2和Oat3对典型底物的摄取,抑制常数(K(i))值为7.02至10.4 microM。在这些细胞中观察到[14C]佐南帕奈摄取呈时间和饱和浓度依赖性增加[米氏常数(K(m))值:13.4至53.6 microM]。丙磺舒和西咪替丁抑制Oats对[14C]佐南帕奈的摄取。在体内实验中,丙磺舒和西咪替丁降低了佐南帕奈肾脏分泌和胆汁排泄的内在清除率。考虑到各转运体的组织分布和定位,这些结果表明,在大鼠中,佐南帕奈通过Oat1和Oat3从血液进入近端肾小管细胞,并且与人类情况不同,还通过Oat2和Oat3进入肝细胞。因此,大鼠和人类之间佐南帕奈排泄的种间差异可能由OATs底物选择性和组织分布的差异来解释。